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between 40 and 80, were recruited by 40 diabetes clinics. A pilot
test-retest validity testing was performed on the same 10 respon-
dents following 2 weeks interval. Ten self-assessment items 
were developed for exploring preference on home glucometers;
3 items were developed for the following domains: needs for
better understanding on diabetes (yes/no); blood glucose self-
monitoring period (<6 months, >6 <18 months, >18 months <3
years, >3 <6 years, >6 years); access to diabetes clinics (regularly
scheduled—yes/no). The Pearson chi-square statistic for two-way
tables was used to test the association between variables; alpha
level of 0.05 was used in all analyses. RESULTS: Patients were
comparable for sex within each class of age (p = 0.670 / 40–
50 years; p = 0.152 / 50–60 years; p = 0.371 /60–70 years; p =
0.370 / 70–80 years). Unsatisﬁed (u) and satisﬁed (s) patients on
general information on diabetes respectively decreased and grew
with increasing age: 60.98% (u), 39.02% (s)/ 40–50 years; 52.14
% (u), 47.86% (s)/ 50–60 years; 45.77% (u), 54.23% (s)/ 60–70
years; 41.67% (u), 58.33% (s),/ 70–80 years (p = 0.05) without
correlating to SBGM period (p = 0.690). Frequency of accesses
to diabetes clinics increases with age from 40 to 80 (p = 0.004).
CONCLUSIONS: Patient perceived dissatisfaction with general
information on diabetes decreases with age and is independent
of SBGM period. Further studies have to be performed to eval-
uate if a better perceived knowledge of the disease can improve
adherence to the treatment and clinical outcomes.
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OBJECTIVES: To assess treatment satisfaction (TS) in a large
population of Type-2 diabetes subjects (T2DM) treated with
insulin glargine (GLAR). METHODS: The 24-week, multina-
tional AT.LANTUS study investigated TS with GLAR initiation
and titration (target FBG £5.5mmol/L) according to two algo-
rithms (Alg): Alg1 was physician based; Alg2 involved subject
self-titration. TS were assessed using the Diabetes Treatment 
Satisfaction Questionnaire status (DTSQs) and change (DTSQc).
Since blood glucose (BG) controls and stability (MODD, MAGE,
8-point BG proﬁles) improved signiﬁcantly, relationships with TS
were explored. RESULTS: TS was evaluated in a group of 
subjects from the eight countries in which the questionnaire was
validated, with 1289 subjects at baseline and 1023 subjects 
at endpoint. Mean baseline DTSQs scores were comparable
between Alg. (26.5 vs. 26.1) with signiﬁcant improvements at
endpoint (both +4.99; p < 0.001). Perceived hyperglycaemia sig-
niﬁcantly decreased (p < 0.001) with both Alg. TS evolution over
time (DTSQc) improved by +13.6 with both Alg. Perceived hypo-
glycaemia decreased in the DTSQc. There were signiﬁcant (p <
0.0001) correlations between fasting BG, mean 8-point BG and
evolution of TS scores and perceived hyperglycaemia. Evolution
of perceived hyperglycaemia was also associated with move-
ments towards BG stability (MAGE: p < 0.0001; MODD: p =
0.0004). A similar pattern of results was seen in the Type-1 pop-
ulation. CONCLUSIONS: This study provides one of the largest
assessments of TS to date and shows that aggressive titration of
GLAR is associated with signiﬁcantly improved TS. Self-titration
was associated with greater improvements in perceived hyper-
glycaemia versus physician-based titration. Perceived overall TS,
hyperglycaemia and hypoglycaemia at endpoint were all corre-
lated with movements towards BG control and stability, provid-
ing potential explanation as to why subjects feel better with
GLAR than their prior therapy.
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OBJECTIVE: To study the relationship of ARMD severity to
anxiety and depression in three European countries: France,
Germany and Italy. METHODS: Patients with wet ARMD 
were included in a retrospective cross-sectional survey. Socio-
demographic and medical data were collected during a visit by
a retina specialist. Anxiety and depression were assessed with the
Hospital Anxiety and Depression Scale (HADS). Two thresholds
were used to dichotomize visual acuity (VA): 20/40 for the best
eye (BE) and 20/200 for the worst eye (WE). Comparisons with
general population matched on age and gender were possible for
the German patients (Hinz, 2004). Analysis of variance was per-
formed to estimate the effect of each eye adjusted on age, gender
and country. RESULTS: A total of 360 patients were included.
The patients (40% male) averaged 77 years of age and 2.3 years
of disease duration. VA was 0.49 LogMAR on the BE the day
of the visit. In the German population, ARMD patient anxiety
score was higher than the general population both in male (5.4
vs. 4.7) and female (7.7 vs. 5.7). Some associations were found
between the severity of the disease and the depression score (BE
P < 0.004) and (WE P < 0.12) while no association was found
on the anxiety score. The prevalence of severe depression accord-
ing to HADS was 0% in the less severe (BE > = 20/40; WE > =
20/200) but 7.6% in the most severe group (BE < 20/40; WE <
20/200). CONCLUSION: Associations were found between
ARMD and depression and anxiety as measured by the HADS.
The severe depression prevalence rate increases when both eyes
are affected by the disease.
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OBJECTIVE: The control of daily IOP variations is a key driver
of visual ﬁeld protection. IOP is rarely measured during the night
in clinical trials. A model was used to predict nocturnal IOP
peaks from daytime measurements. METHODS: Two clinical
trials documenting IOP every 4 hours over several days were
pooled. Nocturnal IOP peak was deﬁned as the maximum value
observed at midnight and 4 AM and was related to diurnal mea-
sures (taken at 8:00, 12:00, 16:00 and 20:00). We employed
neural networks that included linear, radial basis, and multi-layer
perceptron (MLP) selected to minimize error and take into
account diversity. The probability of a nocturnal IOP peak > 17.5
mmHg was estimated. The neural network model was then
applied to data from a trial comparing timolol, travoprost and
latanoprost over 1 year. Drug comparisons were made using a
mixed linear model. RESULTS: 440 pairs of day and night IOP
measures were identiﬁed. A MLP (2:7:1) model was selected
based on sensitivity and speciﬁcity which were both close to one.
The analysis of the MLP output showed afternoon IOPs were
stronger predictors of night peaks than morning IOPs. Applying
